XENON PHARMACEUTICALS INC. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-06-30 was $26.00K, a 60.00% decline year-over-year.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-03-31 was $5.49M, a 376.72% increase year-over-year.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-06-30 was $65.00K.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-03-31 was $1.15M.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $4.96M, a 10457.45% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $47.00K, a 34.29% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $35.00K.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $26.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.49M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $4.96M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $65.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $1.15M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $47.00K 10-K · filed 2026-02-26 | |
| 2023-12-31 | $35.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |